Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Activation of β-catenin/TCF targets following loss of the tumor suppressor SNF5.

Mora-Blanco EL, Mishina Y, Tillman EJ, Cho YJ, Thom CS, Pomeroy SL, Shao W, Roberts CW.

Oncogene. 2014 Feb 13;33(7):933-8. doi: 10.1038/onc.2013.37. Epub 2013 Feb 25.

2.

Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors.

McKenna ES, Tamayo P, Cho YJ, Tillman EJ, Mora-Blanco EL, Sansam CG, Koellhoffer EC, Pomeroy SL, Roberts CW.

Cell Cycle. 2012 May 15;11(10):1956-65. doi: 10.4161/cc.20280. Epub 2012 May 15.

3.

SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.

Wei D, Goldfarb D, Song S, Cannon C, Yan F, Sakellariou-Thompson D, Emanuele M, Major MB, Weissman BE, Kuwahara Y.

Mol Cancer Res. 2014 Nov;12(11):1574-85. doi: 10.1158/1541-7786.MCR-14-0005. Epub 2014 Jul 9.

4.

Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation.

Isakoff MS, Sansam CG, Tamayo P, Subramanian A, Evans JA, Fillmore CM, Wang X, Biegel JA, Pomeroy SL, Mesirov JP, Roberts CW.

Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17745-50. Epub 2005 Nov 21.

5.

Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex.

Wang X, Sansam CG, Thom CS, Metzger D, Evans JA, Nguyen PT, Roberts CW.

Cancer Res. 2009 Oct 15;69(20):8094-101. doi: 10.1158/0008-5472.CAN-09-0733. Epub 2009 Sep 29.

6.

Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5.

Roberts CW, Leroux MM, Fleming MD, Orkin SH.

Cancer Cell. 2002 Nov;2(5):415-25.

7.

Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.

Kim KH, Roberts CW.

Cancer Genet. 2014 Sep;207(9):365-72. doi: 10.1016/j.cancergen.2014.04.004. Epub 2014 Apr 13. Review.

8.
9.

SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.

Kuwahara Y, Wei D, Durand J, Weissman BE.

Mol Cancer Res. 2013 Mar;11(3):251-60. doi: 10.1158/1541-7786.MCR-12-0390. Epub 2013 Jan 30.

10.

Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability.

McKenna ES, Sansam CG, Cho YJ, Greulich H, Evans JA, Thom CS, Moreau LA, Biegel JA, Pomeroy SL, Roberts CW.

Mol Cell Biol. 2008 Oct;28(20):6223-33. doi: 10.1128/MCB.00658-08. Epub 2008 Aug 18.

11.

The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors.

Caramel J, Medjkane S, Quignon F, Delattre O.

Oncogene. 2008 Mar 27;27(14):2035-44. Epub 2007 Oct 8.

PMID:
17922027
12.

The SWI/SNF chromatin-remodeling complex subunit SNF5 is essential for hepatocyte differentiation.

Gresh L, Bourachot B, Reimann A, Guigas B, Fiette L, Garbay S, Muchardt C, Hue L, Pontoglio M, Yaniv M, Klochendler-Yeivin A.

EMBO J. 2005 Sep 21;24(18):3313-24. Epub 2005 Sep 1.

13.

Phospholipase D1 drives a positive feedback loop to reinforce the Wnt/beta-catenin/TCF signaling axis.

Kang DW, Lee SH, Yoon JW, Park WS, Choi KY, Min do S.

Cancer Res. 2010 May 15;70(10):4233-42. doi: 10.1158/0008-5472.CAN-09-3470. Epub 2010 May 4.

14.

Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors.

Wöhrle S, Weiss A, Ito M, Kauffmann A, Murakami M, Jagani Z, Thuery A, Bauer-Probst B, Reimann F, Stamm C, Pornon A, Romanet V, Guagnano V, Brümmendorf T, Sellers WR, Hofmann F, Roberts CW, Graus Porta D.

PLoS One. 2013 Oct 30;8(10):e77652. doi: 10.1371/journal.pone.0077652. eCollection 2013.

15.
16.

[Chromatin remodeling defects and cancer: the SWI/SNF example].

Bourdeaut F, Bièche I.

Bull Cancer. 2012 Dec;99(12):1133-40. doi: 10.1684/bdc.2012.1664. Review. French.

17.

Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway.

Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D, Klekota J, Tamayo P, Nguyen PT, Tolstorukov M, Park PJ, Cho YJ, Hsiao K, Buonamici S, Pomeroy SL, Mesirov JP, Ruffner H, Bouwmeester T, Luchansky SJ, Murtie J, Kelleher JF, Warmuth M, Sellers WR, Roberts CW, Dorsch M.

Nat Med. 2010 Dec;16(12):1429-33. doi: 10.1038/nm.2251. Epub 2010 Nov 14.

18.

Chromatin remodeling: from transcription to cancer.

Yaniv M.

Cancer Genet. 2014 Sep;207(9):352-7. doi: 10.1016/j.cancergen.2014.03.006. Epub 2014 Mar 22. Review.

PMID:
24825771
19.

TCTP promotes glioma cell proliferation in vitro and in vivo via enhanced β-catenin/TCF-4 transcription.

Gu X, Yao L, Ma G, Cui L, Li Y, Liang W, Zhao B, Li K.

Neuro Oncol. 2014 Jan;16(2):217-27. doi: 10.1093/neuonc/not194. Epub 2013 Dec 4.

20.

OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.

Ye GD, Sun GB, Jiao P, Chen C, Liu QF, Huang XL, Zhang R, Cai WY, Li SN, Wu JF, Liu YJ, Wu RS, Xie YY, Chan EC, Liou YC, Li BA.

Gastroenterology. 2016 Mar;150(3):659-671.e16. doi: 10.1053/j.gastro.2015.11.041. Epub 2015 Nov 24.

PMID:
26619963

Supplemental Content

Support Center